Patheon NV Company Profile (NASDAQ:PTHN)

About Patheon NV (PTHN)

Patheon NV logoPatheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTHN
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $25.35
  • 50 Day Moving Average: $27.49
  • 200 Day Moving Average: $28.17
  • 52-Week Range: $23.72 - $32.95
  • Trailing P/E Ratio: 41.15
  • Foreward P/E Ratio: 17.01
  • P/E Growth: 1.15
  • Market Cap: $3.68B
  • Outstanding Shares: 145,136,000

Analyst Ratings

Consensus Ratings for Patheon NV (NASDAQ:PTHN) (?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $31.30 (23.47% upside)

Analysts' Ratings History for Patheon NV (NASDAQ:PTHN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/17/2017Jefferies Group LLCReiterated RatingBuy$33.00 -> $32.00LowView Rating Details
3/17/2017Robert W. BairdDowngradeOutperform -> Neutral$34.00 -> $28.00LowView Rating Details
11/10/2016Leerink SwannInitiated CoverageOutperform$31.00N/AView Rating Details
8/23/2016William BlairInitiated CoverageOutperform -> OutperformN/AView Rating Details
8/16/2016Credit Suisse Group AGInitiated CoverageNeutral$30.00N/AView Rating Details
8/15/2016Raymond James Financial, Inc.Initiated CoverageOutperform$32.50N/AView Rating Details
8/15/2016Evercore ISIInitiated CoverageBuy$33.00N/AView Rating Details
8/15/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
8/15/2016Piper Jaffray CompaniesInitiated CoverageOverweight$32.50N/AView Rating Details
8/15/2016Morgan StanleyInitiated CoverageOverweight$31.00N/AView Rating Details
8/15/2016KeyCorpInitiated CoverageOverweight$33.00N/AView Rating Details
8/15/2016JPMorgan Chase & Co.Initiated CoverageOverweight$30.00N/AView Rating Details
(Data available from 4/24/2015 forward)


Earnings History for Patheon NV (NASDAQ:PTHN)
Earnings by Quarter for Patheon NV (NASDAQ:PTHN)
Earnings History by Quarter for Patheon NV (NASDAQ:PTHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/20171/31/2017$0.22$0.14$463.39 million$457.40 millionViewN/AView Earnings Details
12/20/2016Q416$0.39$0.30$496.27 million$510.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Patheon NV (NASDAQ:PTHN)
2017 EPS Consensus Estimate: $1.36
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.19$0.22$0.21
Q2 20172$0.29$0.37$0.33
Q3 20171$0.38$0.38$0.38
Q4 20172$0.42$0.46$0.44
(Data provided by Zacks Investment Research)


Dividend History for Patheon NV (NASDAQ:PTHN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Patheon NV (NASDAQ:PTHN)
Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
Institutional Ownership by Quarter for Patheon NV (NASDAQ:PTHN)
Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2016Paul S LevyDirectorBuy10,000$29.55$295,500.00View SEC Filing  
9/28/2016Paul S LevyDirectorBuy15,000$29.64$444,600.00View SEC Filing  
9/12/2016Paul S LevyDirectorBuy37,000$28.01$1,036,370.00View SEC Filing  
7/26/2016Jll Patheon Co-Investment FundMajor ShareholderBuy815,730$19.85$16,192,240.50View SEC Filing  
7/26/2016Pamela DaleyDirectorBuy48,800$19.85$968,680.00View SEC Filing  
7/21/2016Philip EykermanDirectorBuy28,000$25.00$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Patheon NV (NASDAQ:PTHN)
Latest Headlines for Patheon NV (NASDAQ:PTHN)
DateHeadline logoDPx Holdings B.V. -- Moody's assigns B2 to DPx Holding's term loan following repricing - April 14 at 6:57 PM logoPatheon NV (PTHN) Receives Average Recommendation of "Buy" from Analysts - March 31 at 1:11 PM logoPatheon Achieved More Outsourced New Drug Approvals Than Any Other Provider According to 2017 PharmSource CMO Scorecard - March 30 at 7:38 PM logoPatheon NV (PTHN) Downgraded by Zacks Investment Research to "Strong Sell" - March 28 at 8:10 AM logoPatheon NV (PTHN) Downgraded to "Strong Sell" at Zacks Investment Research - March 22 at 6:01 PM logoPatheon N.V. downgraded by KeyBanc Capital Mkts and Robert W. Baird - March 18 at 12:31 AM logoPatheon NV (PTHN) Cut to “Neutral” at Robert W. Baird - March 17 at 7:34 PM logoPatheon 1Q Earnings Missed Street Estimates (PTHN) - March 17 at 7:31 PM logoPatheon NV’s (PTHN) “Buy” Rating Reaffirmed at Jefferies Group LLC - March 17 at 5:42 PM logoPatheon 1Q Earnings Missed Analyst Estimates - March 16 at 8:08 PM logoEdited Transcript of PTHN earnings conference call or presentation 16-Mar-17 12:00pm GMT - March 16 at 8:08 PM logoPatheon NV (PTHN) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - March 16 at 10:43 AM logoPatheon Reports Fiscal 2017 First Quarter Results - March 16 at 8:24 AM logo6:36 am Patheon N.V. misses by $0.08, misses on revs; lowers FY17 guidance - March 16 at 8:24 AM logoPatheon Holdings misses Street 1Q forecasts - March 16 at 8:24 AM logoQ1 2017 Patheon NV Earnings Release - Before Market Open - March 16 at 8:24 AM logoPatheon NV (PTHN) Set to Announce Earnings on Thursday - March 15 at 8:19 AM logoPatheon to Announce First Quarter Fiscal Year 2017 Financial Results on March 16, 2017 - March 3 at 8:33 AM logoPatheon Named Supply Chain Resiliency Partner of the Year - March 2 at 7:30 PM logoPatheon Reaches Analyst Target Price - February 24 at 8:34 PM logoPATHEON N.V. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statemen - February 8 at 9:27 PM logoCORRECTING and REPLACING PHOTO Patheon Announces Completion of its Acquisition of State-of-the-Art Manufacturing Site - February 1 at 10:08 PM logoPatheon to Participate in the 35th Annual J.P. Morgan Healthcare Conference - January 4 at 3:18 PM logoInsiders Will Likely Move Pharmaceutical Company Patheon's Stock - December 30 at 7:42 PM logoPATHEON N.V. Financials - December 29 at 7:22 PM logoPATHEON N.V. Files SEC form 10-K, Annual Report - December 23 at 7:31 PM logoEdited Transcript of PTHN earnings conference call or presentation 20-Dec-16 1:00pm GMT - December 21 at 12:03 AM logoPatheon Reports Growth Across All Segments For Fourth Quarter; Provides Outlook for Fiscal Year 2017 - December 20 at 2:00 PM logoQ4 2016 Patheon NV Earnings Release - Before Market Open - December 20 at 2:00 PM logoPATHEON N.V. Files SEC form 8-K, Financial Statements and Exhibits - December 14 at 8:14 PM logoCORRECTING and REPLACING Patheon to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on December 20, 2016; Company to Provide Fiscal 2017 Outlook - December 2 at 12:02 PM logoADDING MULTIMEDIA Patheon to Acquire State-of-the-Art Manufacturing Site - November 29 at 1:59 PM logoFour Underrated Stocks That Big Investors Bought in Q3 - November 21 at 7:31 PM logoPatheon to Participate in Jefferies Global Healthcare Conference - November 4 at 6:33 PM logoJefferies Biotech and Health Care Momentum Stocks to Buy With Big Upside Potential - November 3 at 11:11 AM logoPATHEON N.V. Files SEC form 8-K, Other Events - October 14 at 6:41 PM logoPatheon Announces the Retirement of Stuart Grant - October 11 at 7:13 PM logo8:57 am Patheon announces CFO Stuart Grant plans to retire in 2017 - October 11 at 7:13 PM logoPATHEON N.V. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - October 11 at 7:13 PM logoPATHEON N.V. Files SEC form 10-Q, Quarterly Report - September 14 at 11:17 AM logoPatheon to Participate in Morgan Stanley Global Healthcare Conference - September 9 at 11:40 AM logoPATHEON N.V. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - September 8 at 10:45 AM logoLake Street Capital Likes Felxion's Lead Drug Candidate, Prescribes A Buy Rating - September 6 at 11:40 AM logoCinven to acquires pharmaceutical research firm Bioclinica - August 22 at 6:52 PM logoActavis recalls diabetes drugs made by Durham-based Patheon - August 19 at 6:53 PM logoWhy Every Analyst in the World Loves Patheon Even After a Strong IPO - August 16 at 10:15 AM logoCoverage initiated on Patheon N.V. by Piper Jaffray, JP Morgan, KeyBanc Capital Mkts, Wells Fargo, Robert W. Baird, Morgan Stanley and UBS - August 15 at 7:22 PM logoMorgan Stanley Expects 'Above-Market Organic Growth' For Patheon, Initiates At Overweight - August 15 at 7:22 PM logoPATHEON N.V. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - August 8 at 7:12 PM logoPatheon N.V. -- Moody's affirms DPx Holdings' CFR at B3, downgrades credit facilities and notes. Outlook stable. - August 4 at 7:28 PM


Frequently Asked Questions for Patheon NV (NASDAQ:PTHN)

What is Patheon NV's stock symbol?

Patheon NV trades on the NASDAQ under the ticker symbol "PTHN."

How were Patheon NV's earnings last quarter?

Patheon NV (NASDAQ:PTHN) issued its quarterly earnings results on Thursday, March, 16th. The company reported $0.14 EPS for the quarter, missing the Zacks' consensus estimate of $0.22 by $0.08. The business earned $457.40 million during the quarter, compared to the consensus estimate of $463.39 million. The business's revenue for the quarter was up 12.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.08) earnings per share.

When will Patheon NV make its next earnings announcement?

Patheon NV is scheduled to release their next quarterly earnings announcement on Thursday, March, 16th 2017.

What guidance has Patheon NV issued on next quarter's earnings?

Patheon NV updated its FY17 earnings guidance on Tuesday, December, 20th. The company provided EPS guidance of 1.37-1.51 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.41. The company issued revenue guidance of $2.05 billion, compared to the consensus revenue estimate of $2.06 billion.

Where is Patheon NV's stock going? Where will Patheon NV's stock price be in 2017?

12 equities research analysts have issued twelve-month price targets for Patheon NV's shares. Their predictions range from $28.00 to $33.00. On average, they expect Patheon NV's stock price to reach $31.30 in the next twelve months.

What are analysts saying about Patheon NV stock?

Here are some recent quotes from research analysts about Patheon NV stock:

  • 1. According to Zacks Investment Research, "Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands. " (3/22/2017)
  • 2. Jefferies Group LLC analysts commented, "PTHN's results are a further indication of inherent volatility in the CMO business despite long-cycle contracts. FY17 guidance was reduced on FX headwinds and project delays partially offset by the Roche facility acquisition. LT indicators were more positive and we still believe PTHN can generate above industry growth." (3/17/2017)
  • 3. Morgan Stanley analysts commented, "High operating leverage can drive ~330 bps in EBITDA margin expansion by FY18; we see EPS growth of 58 percent/20 percent in FY17/FY18," analyst Ricky Goldwasser wrote in a note.Goldwasser said the company is poised to expand its CMO share due to its open platform, end-to-end service, quality and global footprint.Related Link: Wells Fargo Initiates Coverage On Patheon At OutperformForward ViewAs such, the analyst believes Patheon can grow its top line at an 11 percent/8 percent CAGR in FY17/FY18, above market growth rates of 5–6 percent, with 209 bps and 121 bps in EBITDA margin expansion in FY17/FY18. The analyst estimates Patheon can grow EBITDA margins from 21.6 percent in FY16 to 24.8 percent in FY18."Patheon is poised to thrive on biologics, the fastest growing area in drug development, given capabilities that span formulation / development as well as API," (8/15/2016)

When did Patheon NV IPO?

(PTHN) raised $625 million in an initial public offering (IPO) on Thursday, July 21st 2016. The company issued 30,500,000 shares at a price of $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.

Who owns Patheon NV stock?

Patheon NV's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Columbus Circle Investors (0.06%). Company insiders that own Patheon NV stock include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman.

Who sold Patheon NV stock? Who is selling Patheon NV stock?

Patheon NV's stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors.

How do I buy Patheon NV stock?

Shares of Patheon NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Patheon NV stock cost?

One share of Patheon NV stock can currently be purchased for approximately $25.35.

Patheon NV (PTHN) Chart for Monday, April, 24, 2017

This page was last updated on 4/24/2017 by Staff